Drug Trial Radar · NCT03470545
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Oct 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
May 29, 2018
Primary completion
Mar 14, 2020
Study completion May 6, 2020
Sponsor
- Lead sponsor
- MyoKardia, Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamtenDrug
mavacamten capsules
PlaceboDrug
placebo oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving A Clinical ResponseTime frame: 30 weeks
Locations
71 sites in 13 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona
Cedars-Sinai Medical Center (Smidt Heart Institute)
Los Angeles, California
UCSF School of Medicine
San Francisco, California
Stanford University
Stanford, California
Yale New Haven Hospital
New Haven, Connecticut
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida
Northwestern University
Chicago, Illinois
University Of Iowa Hospitals And Clinics
Iowa City, Iowa
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Spectrum Health
Grand Rapids, Michigan
Washington University School of Medicine
St Louis, Missouri
NYU Langone Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Carolinas Medical Center
Charlotte, North Carolina
Duke Cardiology at Southpoint
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Oregon Health & Science University
Portland, Oregon
St. Luke's Cardiology Associates
Bethlehem, Pennsylvania
University of Pennsylvania (Penn Heart and Vascular Center)
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Presbyterian
Pittsburgh, Pennsylvania
Methodist University Hospital
Memphis, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
University of Texas Houston Medical School
Houston, Texas
Intermountain Medical Center
Salt Lake City, Utah
University of Utah
Salt Lake City, Utah
University of Virginia Health System
Charlottesville, Virginia
University of Washington Medical Center
Seattle, Washington
Hôpital Erasme
Brussels, Belgium
UZ Antwerpen
Edegem, Antwerpen, Belgium
Onze-Lieve-Vrouwziekenhuis
Aalst, Oost-Vlaanderen, Belgium
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Institut Klinicke a Experimentalni Mediciny
Prague, Czechia
Aarhus Universitetshospital
Aarhus N, Denmark
Bispebjerg Hospital
København NV, Denmark
Odense Universitetshospital
Odense, Denmark
Groupe Hospitalier Pitié Salpétrière
Paris, France
Hôpital Européen Georges Pompidou
Paris, France
Hôpital de Rangueil
Toulouse, France
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.